<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18915" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cardiomegaly</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Amin</surname>
            <given-names>Hina</given-names>
          </name>
          <aff>SUNY Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Siddiqui</surname>
            <given-names>Waqas J.</given-names>
          </name>
          <aff>Drexel University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hina Amin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Waqas Siddiqui declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>11</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18915.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Cardiomegaly is an umbrella designation for various conditions leading to heart enlargement, which usually remains undiagnosed until the symptoms ensue. It has become increasingly prevalent and carries a high mortality. Cardiomegaly means enlargement of the heart. The definition is when the transverse diameter of the cardiac silhouette is greater than or equal to 50% of the transverse diameter of the chest (increased cardiothoracic ratio) on a posterior-anterior projection of a chest radiograph or a computed tomography. This activity reviews the etiology, epidemiology, pathophysiology, signs and symptoms, evaluation, and management of cardiomegaly. It highlights the role of the interprofessional team in improving outcomes for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the risk factors for developing cardiomegaly.</p></list-item><list-item><p>Assess the typical presentation of a patient with cardiomegaly.</p></list-item><list-item><p>Evaluate&#x000a0;the treatment considerations in a patient with cardiomegaly.</p></list-item><list-item><p>Communicate&#x000a0;the importance of improving care coordination amongst the interprofessional team to enhance care delivery for patients affected by cardiomegaly.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18915&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18915">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18915.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Cardiomegaly means enlargement of the heart. The definition is when the transverse diameter of the cardiac silhouette is greater than or equal to 50% of the transverse diameter of the chest (increased cardiothoracic ratio) on a posterior-anterior projection of a chest radiograph or a computed tomography. It should not be confused with an enlargement of the cardiomediastinal outline. Cardiomegaly is usually a manifestation of another pathologic process and presents with several forms of primary or acquired cardiomyopathies. It may involve enlargement of the right, left, or ventricles or the atria. Many types of cardiomyopathy, such as dilated cardiomyopathy, are characterized by left ventricular dilation and systolic dysfunction, although right ventricular impairment and diastolic dysfunction can also develop.<xref ref-type="bibr" rid="article-18915.r1">[1]</xref></p>
      </sec>
      <sec id="article-18915.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Several etiologies have been attributed to the development of cardiomegaly, resulting in either dilated or hypertrophic cardiomyopathy. These include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Coronary artery disease, including myocardial infarction and ischemia (most common cause)<xref ref-type="bibr" rid="article-18915.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Hypertensive heart disease<xref ref-type="bibr" rid="article-18915.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Valvular heart diseases, including stenosis or regurgitation of the aortic, mitral, pulmonary, or tricuspid valves and sub-acute bacterial endocarditis<xref ref-type="bibr" rid="article-18915.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Congenital heart disorders, including atrial septal defect, ventricular septal defect, patent ductus arteriosus, tetralogy of Fallot, Ebstein anomaly, and coarctation of the aorta</p>
          </list-item>
          <list-item>
            <p>Pulmonary diseases such as primary pulmonary hypertension, chronic obstructive pulmonary disease, obesity hypoventilation syndrome, and pulmonary embolism&#x000a0;with cor-pulmonale<xref ref-type="bibr" rid="article-18915.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Infectious myocarditis secondary to viral infection (most common), HIV, Chaga disease<xref ref-type="bibr" rid="article-18915.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Infiltrative/deposition diseases, such as amyloidosis, sarcoidosis, hypothyroidism, acromegaly, and hemochromatosis<xref ref-type="bibr" rid="article-18915.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Toxin-induced cardiomyopathy (alcohol, cocaine, chemotherapeutic agents such as doxorubicin, cyclophosphamide, trastuzumab, and radiation)<xref ref-type="bibr" rid="article-18915.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Autoimmune cardiomyopathy, including eosinophilic myocarditis, idiopathic giant cell myocarditis, and collagen vascular disease</p>
          </list-item>
          <list-item>
            <p>Arrhythmia, including atrial fibrillation and flutter leading to tachycardia-induced cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy with the fibro-fatty replacement of RV</p>
          </list-item>
          <list-item>
            <p>Systemic diseases leading to a high output state, including anemia, hyperthyroidism, vitamin B1 deficiency (&#x0201c;beriberi&#x0201d;), and AV fistula<xref ref-type="bibr" rid="article-18915.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Physiologic conditions include stress cardiomyopathy, exercise-induced cardiomegaly or &#x0201c;athletic&#x0201d; heart, and pregnancy</p>
          </list-item>
          <list-item>
            <p>Familial cardiomyopathy, hypertrophic obstructive cardiomyopathy<xref ref-type="bibr" rid="article-18915.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Peripartum cardiomyopathy<xref ref-type="bibr" rid="article-18915.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Idiopathic cardiomyopathy<xref ref-type="bibr" rid="article-18915.r12">[12]</xref><xref ref-type="bibr" rid="article-18915.r13">[13]</xref><xref ref-type="bibr" rid="article-18915.r14">[14]</xref>&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18915.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Enlargement of the heart, both in the form of dilatation or hypertrophy, leads to a spectrum of clinical heart failure syndrome, with a prevalence of nearly 5.8 million people in the United States. Heart failure with preserved ejection fraction represents more than half of these cases. The incidence of heart failure increases with age, male gender, and African American race. About half of the people diagnosed with heart failure die within&#x000a0;5 years of diagnosis.<xref ref-type="bibr" rid="article-18915.r15">[15]</xref>&#x000a0;In adults, dilated cardiomyopathy is more prevalent in men than in women. In the pediatric population, the&#x000a0;annual incidence is 0.57 cases per 100,000 per year (higher in boys than girls,&#x000a0;in Blacks than Whites, and in babies&#x000a0;less than&#x000a0;1 year than in children). Two-thirds of children have idiopathic disease.<xref ref-type="bibr" rid="article-18915.r16">[16]</xref>&#x000a0;Hypertrophic cardiomyopathy is a global disease, with cases in over 50 countries on all continents, affecting both sexes&#x000a0;and of&#x000a0;several ethnic and racial origins.<xref ref-type="bibr" rid="article-18915.r17">[17]</xref>&#x000a0;In diverse regions, such as the USA, Europe, China, Japan, and East Africa, hypertrophic cardiomyopathy is a common genetic&#x000a0;cardiac disease,&#x000a0;having&#x000a0;a prevalence of around 1 in 500 in the general population.<xref ref-type="bibr" rid="article-18915.r18">[18]</xref></p>
      </sec>
      <sec id="article-18915.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The development of cardiac remodeling and hypertrophy is complex, with genetic and non-genetic components. The most critical pathophysiological changes leading to cardiomegaly include dilated hypertrophy, fibrosis, and contractile malfunction. Contractile dysfunction and abnormal myocardial remodeling can lead to hypertrophic cardiomyopathy or dilated cardiomyopathy. Mechanical stretching, circulating neurohormones, and oxidative stress&#x000a0;are significant stimuli for the signal transduction of inflammatory cytokines and MAP kinase in cardiomyocytes. Signal transduction leads to changes in structural proteins and proteins that regulate excitation-contraction. Dilated cardiomyopathy&#x000a0;mutations result in a reduced force of the sarcomere contraction and a reduction in sarcomere content. Hypertrophic cardiomyopathy mutations result in a molecular phenotype of hyperdynamic contractility, poor relaxation, and increased energy consumption.<xref ref-type="bibr" rid="article-18915.r19">[19]</xref><xref ref-type="bibr" rid="article-18915.r20">[20]</xref></p>
        <p>Pathophysiological mechanisms can vary depending on the underlying cause of cardiomyopathy. For instance, in diabetic cardiomyopathy,&#x000a0;fatty acid metabolism is enhanced, glucose oxidation is suppressed, and intracellular signaling is modified, causing impairment in multiple steps of inefficient energy production, excitation-contraction coupling, and increased potential for ischemia/reperfusion injury. In&#x000a0;alcohol-induced cardiomyopathy, cell death&#x000a0;due to apoptosis ultimately leads to changes in&#x000a0;various aspects of myocyte function.<xref ref-type="bibr" rid="article-18915.r21">[21]</xref>&#x000a0;In mitochondrial cardiomyopathy,&#x000a0;multiple biochemical pathways involving mitochondria&#x000a0;impair oxidative phosphorylation.<xref ref-type="bibr" rid="article-18915.r22">[22]</xref>&#x000a0;Peripartum cardiomyopathy is associated with genetic alterations, angiogenic imbalance, oxidative stress, and&#x000a0;the production of a prolactin fragment.<xref ref-type="bibr" rid="article-18915.r23">[23]</xref>&#x000a0;In hypertrophic cardiomyopathy,&#x000a0;ventricular hypertrophy results in a dynamic pressure gradient across the left ventricular outflow tract, associated with further narrowing during systole. During this cardiac cycle, the mitral valve is pulled towards the septum by several proposed mechanisms: contraction of the papillary muscles, abnormal location in the outflow tract, and low pressure that occurs as blood is ejected at high velocity through a narrowed outflow tract (Venturi effect).<xref ref-type="bibr" rid="article-18915.r24">[24]</xref></p>
      </sec>
      <sec id="article-18915.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Many patients with cardiomegaly are asymptomatic, and the presence of symptoms alone is neither sensitive nor specific to diagnosis. The diagnosis of cardiomegaly&#x000a0;is based on imaging, and history is only helpful in determining the cause of heart failure symptoms, resulting in systemic congestion and impaired organ perfusion.<xref ref-type="bibr" rid="article-18915.r25">[25]</xref>&#x000a0;A detailed history should elicit the presence or absence of the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Shortness of breath on exertion or rest, orthopnea, and paroxysmal nocturnal dyspnea</p>
          </list-item>
          <list-item>
            <p>Peripheral edema and abdominal distension</p>
          </list-item>
          <list-item>
            <p>Fatigue and poor exercise tolerance</p>
          </list-item>
          <list-item>
            <p>Palpitations, lightheadedness, or syncope<xref ref-type="bibr" rid="article-18915.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p>Angina</p>
          </list-item>
          <list-item>
            <p>Anorexia, nausea, and early satiety</p>
          </list-item>
          <list-item>
            <p>Family history of cardiomyopathy</p>
          </list-item>
          <list-item>
            <p>Recent pregnancy/childbirth</p>
          </list-item>
          <list-item>
            <p>Comorbid illnesses, such as hypertension and diabetes mellitus</p>
          </list-item>
        </list>
        <p>It is worth mentioning that cardiac function is adequate during rest and may become inadequate with exertion. Hence, it is not uncommon for patients to be asymptomatic at rest and experience symptoms only on exertion. The New York Heart Association classifies the severity of disease based on symptoms, where class I disease is asymptomatic with ordinary physical activity, and class IV denotes symptoms with rest.&#x000a0;Perhaps the most specific sign of cardiomegaly is a displaced maximal impulse (PMI) point.<xref ref-type="bibr" rid="article-18915.r27">[27]</xref> The precordial examination reveals a displaced PMI, usually below the 5th intercostal space, lateral to the midclavicular line, and palpable across&#x000a0;2 intercostal spaces. Sustained PMI is a sign of severe left ventricular hypertrophy. A sustained and prolonged left parasternal heave is indicative of right ventricular hypertrophy. Another physical finding observed in cardiomegaly is the holosystolic murmur of mitral or tricuspid regurgitation resulting from dilatation of the mitral annulus and displacement of papillary muscles with abnormal myocardial remodeling. Other exam findings may be seen depending on the presence or absence of decompensated heart failure. In such cases, a detailed physical exam may reveal the following abnormalities:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Sinus tachycardia resulting from increased sympathetic drive</p>
          </list-item>
          <list-item>
            <p>Diminished pulse pressure reflecting reduced stroke volume</p>
          </list-item>
          <list-item>
            <p>Varying degrees of respiratory distress based on the severity of the disease</p>
          </list-item>
          <list-item>
            <p>Cool, cyanotic extremities secondary to peripheral vasoconstriction</p>
          </list-item>
          <list-item>
            <p>Jugular venous distension or positive abdominojugular reflex indicating elevated right-sided filling pressures</p>
          </list-item>
          <list-item>
            <p>Ascites, hepatomegaly, and peripheral edema result from increased pressure in the hepatic veins and systemic veins<xref ref-type="bibr" rid="article-18915.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>Pulmonary crackles resulting from elevated left-sided filling pressure and transudation of fluid into alveoli</p>
          </list-item>
          <list-item>
            <p>S3 gallop in early diastole resulting from volume overload and systolic dysfunction; S4 gallop in late diastole resulting from diastolic dysfunction</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18915.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnosis of cardiomegaly is primarily through imaging techniques that assess the heart's size and function. Diagnostic testing includes&#x000a0;1 of the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>A chest X-ray with an enlarged cardiac silhouette and a cardiothoracic ratio of more than 50% suggests cardiomegaly.<xref ref-type="bibr" rid="article-18915.r29">[29]</xref> Further delineation of specific chamber enlargement is also possible. Right ventricle (RV) enlargement produces an upward deviation of the left apical margin, while left ventricle enlargement leads to a leftward displacement of the left heart border. Right atrial (RA) enlargement increases the right heart border convexity. Left atrial enlargement and its extension to the right leads to a "double density" sign.<xref ref-type="bibr" rid="article-18915.r30">[30]</xref> Also, in heart failure, cephalization of the pulmonary vessels, Kerley B-lines, pulmonary edema, and pleural effusions are present.</p>
          </list-item>
          <list-item>
            <p>A transthoracic echocardiogram can assess the left ventricle, right ventricle, atrial size, and systolic/diastolic function. It can also determine valve structure and function and detect wall motion changes that suggest ischemia.</p>
          </list-item>
          <list-item>
            <p>Cardiac MRI is an emerging diagnostic modality for accurately evaluating&#x000a0;left and&#x000a0;right ventricle mass, size, and function. It can also characterize ischemic and non-ischemic causes such as myocarditis.</p>
          </list-item>
          <list-item>
            <p>An electrocardiogram (ECG) can reveal non-specific changes, including left ventricle/right ventricle hypertrophy, low voltage QRS in case of fibrosis/dilated cardiomyopathy, conduction abnormality, arrhythmia, premature ventricular complexes (PVCs), ST-T wave changes, and Q waves suggestive of prior myocardial infarction.</p>
          </list-item>
          <list-item>
            <p>Serum levels of brain natriuretic peptide (pro-BNP), troponin I and T, renal function, and liver function tests are helpful in the setting of heart failure.<xref ref-type="bibr" rid="article-18915.r31">[31]</xref></p>
          </list-item>
          <list-item>
            <p>Stress test or coronary angiogram to evaluate for coronary artery disease.</p>
          </list-item>
          <list-item>
            <p>Despite standard workup, the etiology of cardiomegaly is often unclear. In such cases, additional testing may be pursued to determine the underlying etiology.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18915.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment of mild cardiomegaly centers on the treatment of the underlying condition. Standard heart failure treatment guidelines also apply to moderate to severe cardiomegaly associated with heart failure.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients at risk of cardiomyopathy benefit from risk factor modification such as smoking cessation, limiting alcohol intake, weight loss, exercise, and consuming a healthy diet. Recommendations include treating underlying risk factors such as hypertension, dyslipidemia, and diabetes. Other underlying conditions, including obstructive sleep apnea, arrhythmias, anemia, and thyroid disorders, also require treatment.<xref ref-type="bibr" rid="article-18915.r32">[32]</xref></p>
          </list-item>
          <list-item>
            <p>Patients with early onset cardiomyopathy who are asymptomatic are managed with risk factor modification and the addition of an angiotensin-converting enzyme (ACE) inhibitor or ARB (if intolerant to ACE) and beta-blocker if there is a history of&#x000a0;myocardial infarction or reduced ejection fraction.<xref ref-type="bibr" rid="article-18915.r33">[33]</xref></p>
          </list-item>
          <list-item>
            <p>Patients with cardiomyopathy and symptoms of heart failure are managed with diuretics and salt restriction in addition to the above therapies.<xref ref-type="bibr" rid="article-18915.r34">[34]</xref> All such patients should receive an ACE inhibitor or ARB (if intolerant to ACE) and a beta-blocker if they have reduced ejection fraction. An ARNI (ARB plus neprilysin inhibitor) is occasionally used instead of ACE/ARB to reduce hospitalization in heart failure and mortality. For patients with moderate to severe symptoms and reduced ejection fraction, the addition of aldosterone antagonists further reduces mortality. A hydralazine/nitrate combination, when added to ACE inhibitor, beta blocker, and diuretics, improves outcomes in Black patients. Digoxin is added in some patients to reduce the rate of hospitalization with heart failure; however, it does not impact outcomes. An ICD (implantable cardioverter defibrillator) is placed in patients with an ejection fraction&#x000a0;of 35% or less to reduce mortality from sudden cardiac death. Cardiac resynchronization is performed with or without ICD in patients with an ejection fraction&#x000a0;of 35% or less and moderate to severe symptoms with evidence of left bundle branch block.</p>
          </list-item>
          <list-item>
            <p>Patients with refractory heart failure should receive optimal medical management. Also, eligible patients can be considered for cardiac transplantation and bridge therapy, such as ventricle assist devices.<xref ref-type="bibr" rid="article-18915.r35">[35]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>Of special consideration is that no pharmacologic agent has shown benefits in heart failure with preserved ejection fraction. The mainstay of treatment is&#x000a0;controlling underlying conditions such as hypertension, heart rate in patients with atrial fibrillation, ischemia with medication or coronary intervention, and diuretics for fluid overload. Patients with asymptomatic hypertrophic obstructive cardiomyopathy can be safely monitored. Patients with symptoms of&#x000a0;heart failure and left ventricular outflow tract obstruction may benefit from negative inotropes such as beta-blockers, calcium channel blockers, or dipyridamole. Vasodilators and diuretics should be avoided in such patients. Some novel treatment strategies are being studied through recent evidence favoring the supplementation of endogenous antioxidants for managing diabetic cardiomyopathy. These strategies include gene therapy targeting the phosphoinositide 3-kinase signaling pathway and miRNA dysregulation. A future strategy could be to target redox stress and protective protein signaling pathways for combating the ever-rising incidence of heart failure in patients with diabetes.<xref ref-type="bibr" rid="article-18915.r36">[36]</xref></p>
      </sec>
      <sec id="article-18915.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differentials of cardiomegaly include disorders that can result in an enlarged cardiomediastinal silhouette on a frontal (or posteroanterior) chest X-ray. These include:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Pericardial effusion</p>
          </list-item>
          <list-item>
            <p>Anterior mediastinal mass</p>
          </list-item>
          <list-item>
            <p>Prominent epicardial fat pad</p>
          </list-item>
          <list-item>
            <p>Mediastinal widening secondary to pulmonary/aortic pathology</p>
          </list-item>
          <list-item>
            <p>Expiratory radiograph</p>
          </list-item>
          <list-item>
            <p>AP projection</p>
          </list-item>
          <list-item>
            <p>Thymus tumor<xref ref-type="bibr" rid="article-18915.r37">[37]</xref></p>
          </list-item>
          <list-item>
            <p>Cardiac neoplasms</p>
          </list-item>
          <list-item>
            <p>Myocarditis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18915.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Despite the advent of new therapies,&#x000a0;mortality remains high in patients with&#x000a0;symptomatic heart failure. Roughly, 1-year mortality is 30%, while 5-year mortality is 50%. The severity of symptoms, advanced age, and&#x000a0;heart failure hospitalization are significant predictors of mortality in heart failure.<xref ref-type="bibr" rid="article-18915.r38">[38]</xref>&#x000a0;Overall, the prognosis of patients with dilated cardiomyopathy is guarded. Most patients eventually end up with chronic heart failure. Many become candidates for a heart transplant or an assist device, which also adds morbidity. Almost 50% of patients are dead within&#x000a0;5 years. Mortality rates of 1% to 4% have been reported in patients with hypertrophic cardiomyopathy, but these numbers have greatly improved in the past&#x000a0;2 decades. Even though most patients have no symptoms, the first clinical presentation is often sudden death from malignant arrhythmias. The highest mortality is in young people.</p>
      </sec>
      <sec id="article-18915.s11" sec-type="Complications">
        <title>Complications</title>
        <p>As cardiomegaly can be secondary to various underlying pathologies, resulting complications tend to vary a great deal as well. The following are a few important complications to be aware of:</p>
        <list list-type="bullet">
          <list-item>
            <p>Decompensated heart failure</p>
          </list-item>
          <list-item>
            <p>Sudden cardiac death and malignant ventricular arrhythmias<xref ref-type="bibr" rid="article-18915.r39">[39]</xref></p>
          </list-item>
          <list-item>
            <p>Thromboembolism secondary to mural thrombi</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18915.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education regarding medication compliance, dietary restrictions, and regular follow-up is critical to achieving the best outcomes. In addition, families should go through an investigative procedure when someone is found to have hypertrophic obstructive cardiomyopathy.</p>
      </sec>
      <sec id="article-18915.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Cardiac transplantation is an emerging treatment for patients with refractory end-stage heart failure. Patients undergo cardiopulmonary assessment and prognostication using specific scoring systems to determine their candidacy for transplant. Patients with systemic illness, life expectancy under&#x000a0;2 years, active substance and alcohol abuse, and non-compliance with medical therapy are considered poor candidates for cardiac transplantation. Patients should have a robust psychosocial support system to qualify. A risk-benefit assessment is necessary before the patient qualifies for the transplant list. Patients who are not candidates for a cardiac transplant can qualify for a durable ventricular assist device.<xref ref-type="bibr" rid="article-18915.r40">[40]</xref></p>
      </sec>
      <sec id="article-18915.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Heart failure readmissions account for a majority of national healthcare expenditures. Support programs are operating nationwide to minimize the number of congestive heart failure-related hospitalizations and reduce the economic strain. These programs utilize a collaborative approach with many integrated disciplines and providers. Some inpatient strategies include guideline-based care, discharge support by nurses, patient education, medication reconciliation by the pharmacist, and early post-discharge follow-up. A board-certified cardiology pharmacist can assist clinicians in selecting medications for blood pressure control and other factors where medication can provide ancillary benefits. Cardiology-specialized nurses are also valuable interprofessional team members, coordinating activities between various specialists and other clinicians and providing patient counseling. Promising outpatient strategies include interprofessional team engagement in&#x000a0;heart failure clinics and disease management programs that make in-person contact with patients and provide individualized education.<xref ref-type="bibr" rid="article-18915.r41">[41]</xref>&#x000a0;Cardiomegaly and&#x000a0;heart failure require an interprofessional team approach that includes physicians and specialists, specialty-trained nurses, pharmacists, and therapists working collaboratively to make optimal therapeutic choices that lead to the best possible patient outcomes. This interprofessional approach requires open communication between all members of the care team and accurate, updated documentation to be effective.</p>
      </sec>
      <sec id="article-18915.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18915&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18915">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/heart-health/cardiomegaly-enlarged-heart/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=18915">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18915/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18915">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18915.s16">
        <title>References</title>
        <ref id="article-18915.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jefferies</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Towbin</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Dilated cardiomyopathy.</article-title>
            <source>Lancet</source>
            <year>2010</year>
            <month>Feb</month>
            <day>27</day>
            <volume>375</volume>
            <issue>9716</issue>
            <fpage>752</fpage>
            <page-range>752-62</page-range>
            <pub-id pub-id-type="pmid">20189027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heusch</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Libby</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gersh</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yellon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lopaschuk</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Opie</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular remodelling in coronary artery disease and heart failure.</article-title>
            <source>Lancet</source>
            <year>2014</year>
            <month>May</month>
            <day>31</day>
            <volume>383</volume>
            <issue>9932</issue>
            <fpage>1933</fpage>
            <page-range>1933-43</page-range>
            <pub-id pub-id-type="pmid">24831770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berk</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Fujiwara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lehoux</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>ECM remodeling in hypertensive heart disease.</article-title>
            <source>J Clin Invest</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>117</volume>
            <issue>3</issue>
            <fpage>568</fpage>
            <page-range>568-75</page-range>
            <pub-id pub-id-type="pmid">17332884</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chin</surname>
                <given-names>CWL</given-names>
              </name>
              <name>
                <surname>Everett</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kwiecinski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vesey</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Yeung</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Esson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Koo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mirsadraee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Japp</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Prasad</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Semple</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Dweck</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis.</article-title>
            <source>JACC Cardiovasc Imaging</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>10</volume>
            <issue>11</issue>
            <fpage>1320</fpage>
            <page-range>1320-1333</page-range>
            <pub-id pub-id-type="pmid">28017384</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baguet</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Barone-Rochette</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tamisier</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>P&#x000e9;pin</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of cardiac dysfunction in obstructive sleep apnea.</article-title>
            <source>Nat Rev Cardiol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>9</volume>
            <issue>12</issue>
            <fpage>679</fpage>
            <page-range>679-88</page-range>
            <pub-id pub-id-type="pmid">23007221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cunha-Neto</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chevillard</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Chagas disease cardiomyopathy: immunopathology and genetics.</article-title>
            <source>Mediators Inflamm</source>
            <year>2014</year>
            <volume>2014</volume>
            <fpage>683230</fpage>
            <pub-id pub-id-type="pmid">25210230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohty</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Damy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cosnay</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Echahidi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Casset-Senon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Virot</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jaccard</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cardiac amyloidosis: updates in diagnosis and management.</article-title>
            <source>Arch Cardiovasc Dis</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>106</volume>
            <issue>10</issue>
            <fpage>528</fpage>
            <page-range>528-40</page-range>
            <pub-id pub-id-type="pmid">24070600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Renu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>V G</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>P B</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Arunachalam</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Molecular mechanism of doxorubicin-induced cardiomyopathy - An update.</article-title>
            <source>Eur J Pharmacol</source>
            <year>2018</year>
            <month>Jan</month>
            <day>05</day>
            <volume>818</volume>
            <fpage>241</fpage>
            <page-range>241-253</page-range>
            <pub-id pub-id-type="pmid">29074412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Helali</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ziaeian</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Lankarani-Fard</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Thiamine and Heart Failure: Challenging Cases of Modern-Day Cardiac Beriberi.</article-title>
            <source>Mayo Clin Proc Innov Qual Outcomes</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>221</fpage>
            <page-range>221-225</page-range>
            <pub-id pub-id-type="pmid">31193878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prinz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Farr</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hering</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Horstkotte</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Faber</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The diagnosis and treatment of hypertrophic cardiomyopathy.</article-title>
            <source>Dtsch Arztebl Int</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>108</volume>
            <issue>13</issue>
            <fpage>209</fpage>
            <page-range>209-15</page-range>
            <pub-id pub-id-type="pmid">21505608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hilfiker-Kleiner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sliwa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Drexler</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Peripartum cardiomyopathy: recent insights in its pathophysiology.</article-title>
            <source>Trends Cardiovasc Med</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>173</fpage>
            <page-range>173-9</page-range>
            <pub-id pub-id-type="pmid">18790387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Felker</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Hare</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hruban</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Clemetson</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Baughman</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Kasper</surname>
                <given-names>EK</given-names>
              </name>
            </person-group>
            <article-title>Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy.</article-title>
            <source>N Engl J Med</source>
            <year>2000</year>
            <month>Apr</month>
            <day>13</day>
            <volume>342</volume>
            <issue>15</issue>
            <fpage>1077</fpage>
            <page-range>1077-84</page-range>
            <pub-id pub-id-type="pmid">10760308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goff</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Calkins</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Sudden death related cardiomyopathies - Hypertrophic cardiomyopathy.</article-title>
            <source>Prog Cardiovasc Dis</source>
            <year>2019</year>
            <season>May-Jun</season>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>212</fpage>
            <page-range>212-216</page-range>
            <pub-id pub-id-type="pmid">31004609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vischer</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Castelletti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Syrris</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McKenna</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Pantazis</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Heart failure in patients with arrhythmogenic right ventricular cardiomyopathy: Genetic characteristics.</article-title>
            <source>Int J Cardiol</source>
            <year>2019</year>
            <month>Jul</month>
            <day>01</day>
            <volume>286</volume>
            <fpage>99</fpage>
            <page-range>99-103</page-range>
            <pub-id pub-id-type="pmid">30765282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bui</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Horwich</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and risk profile of heart failure.</article-title>
            <source>Nat Rev Cardiol</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-41</page-range>
            <pub-id pub-id-type="pmid">21060326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Towbin</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lowe</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Colan</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Sleeper</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Orav</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Clunie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Messere</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Lurie</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Canter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wilkinson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Lipshultz</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Incidence, causes, and outcomes of dilated cardiomyopathy in children.</article-title>
            <source>JAMA</source>
            <year>2006</year>
            <month>Oct</month>
            <day>18</day>
            <volume>296</volume>
            <issue>15</issue>
            <fpage>1867</fpage>
            <page-range>1867-76</page-range>
            <pub-id pub-id-type="pmid">17047217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maron</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Hypertrophic cardiomyopathy: an important global disease.</article-title>
            <source>Am J Med</source>
            <year>2004</year>
            <month>Jan</month>
            <day>01</day>
            <volume>116</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <page-range>63-5</page-range>
            <pub-id pub-id-type="pmid">14706671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Charron</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Carrier</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ledeuil</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cheav</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pichereau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Benaiche</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Isnard</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dubourg</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Burban</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gueffet</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Millaire</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Desnos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hainque</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Komajda</surname>
                <given-names>M</given-names>
              </name>
              <collab>EUROGENE Heart Failure Project</collab>
            </person-group>
            <article-title>Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy.</article-title>
            <source>Circulation</source>
            <year>2003</year>
            <month>May</month>
            <day>06</day>
            <volume>107</volume>
            <issue>17</issue>
            <fpage>2227</fpage>
            <page-range>2227-32</page-range>
            <pub-id pub-id-type="pmid">12707239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garfinkel</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Seidman</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Seidman</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Genetic Pathogenesis of Hypertrophic and Dilated Cardiomyopathy.</article-title>
            <source>Heart Fail Clin</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>139</fpage>
            <page-range>139-146</page-range>
            <pub-id pub-id-type="pmid">29525643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rababa'h</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Guillory</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Mustafa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hijjawi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Oxidative Stress and Cardiac Remodeling: An Updated Edge.</article-title>
            <source>Curr Cardiol Rev</source>
            <year>2018</year>
            <month>Mar</month>
            <day>14</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-59</page-range>
            <pub-id pub-id-type="pmid">29332590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piano</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Alcoholic cardiomyopathy: incidence, clinical characteristics, and pathophysiology.</article-title>
            <source>Chest</source>
            <year>2002</year>
            <month>May</month>
            <volume>121</volume>
            <issue>5</issue>
            <fpage>1638</fpage>
            <page-range>1638-50</page-range>
            <pub-id pub-id-type="pmid">12006456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyers</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Basha</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Koenig</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Mitochondrial cardiomyopathy: pathophysiology, diagnosis, and management.</article-title>
            <source>Tex Heart Inst J</source>
            <year>2013</year>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>385</fpage>
            <page-range>385-94</page-range>
            <pub-id pub-id-type="pmid">24082366</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hilfiker-Kleiner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sliwa</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology and epidemiology of peripartum cardiomyopathy.</article-title>
            <source>Nat Rev Cardiol</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>364</fpage>
            <page-range>364-70</page-range>
            <pub-id pub-id-type="pmid">24686946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poliac</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Barron</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Maron</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Hypertrophic cardiomyopathy.</article-title>
            <source>Anesthesiology</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>104</volume>
            <issue>1</issue>
            <fpage>183</fpage>
            <page-range>183-92</page-range>
            <pub-id pub-id-type="pmid">16394705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rocklin</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>The Role of the Clinical Examination in Patients With Heart Failure: E-Z CVP.</article-title>
            <source>JACC Heart Fail</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>6</volume>
            <issue>11</issue>
            <fpage>972</fpage>
            <page-range>972-973</page-range>
            <pub-id pub-id-type="pmid">30384921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Frenneaux</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Syncope in hypertrophic cardiomyopathy: mechanisms and consequences for treatment.</article-title>
            <source>Europace</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>9</volume>
            <issue>9</issue>
            <fpage>817</fpage>
            <page-range>817-22</page-range>
            <pub-id pub-id-type="pmid">17522079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Razi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Estrada</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Doll</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>KT</given-names>
              </name>
            </person-group>
            <article-title>Bedside hand-carried ultrasound by internal medicine residents versus traditional clinical assessment for the identification of systolic dysfunction in patients admitted with decompensated heart failure.</article-title>
            <source>J Am Soc Echocardiogr</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>24</volume>
            <issue>12</issue>
            <fpage>1319</fpage>
            <page-range>1319-24</page-range>
            <pub-id pub-id-type="pmid">21885245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chinnaiyan</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Leff</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Marsalese</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Constrictive pericarditis versus restrictive cardiomyopathy: challenges in diagnosis and management.</article-title>
            <source>Cardiol Rev</source>
            <year>2004</year>
            <season>Nov-Dec</season>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>314</fpage>
            <page-range>314-20</page-range>
            <pub-id pub-id-type="pmid">15476569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mensah</surname>
                <given-names>YB</given-names>
              </name>
              <name>
                <surname>Mensah</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Asiamah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gbadamosi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Idun</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Brakohiapa</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Oddoye</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Establishing the Cardiothoracic Ratio Using Chest Radiographs in an Indigenous Ghanaian Population: A Simple Tool for Cardiomegaly Screening.</article-title>
            <source>Ghana Med J</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>49</volume>
            <issue>3</issue>
            <fpage>159</fpage>
            <page-range>159-64</page-range>
            <pub-id pub-id-type="pmid">26693191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sethi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Singla</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Biatrial enlargement: an unusual cause of massive cardiomegaly.</article-title>
            <source>BMJ Case Rep</source>
            <year>2013</year>
            <month>Jan</month>
            <day>31</day>
            <volume>2013</volume>
            <pub-id pub-id-type="pmid">23376674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Knudsen</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Omland</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Clopton</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Westheim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Storrow</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>McCord</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nowak</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aumont</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Duc</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hollander</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>McCullough</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Maisel</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic value of B-Type natriuretic peptide and chest radiographic findings in patients with acute dyspnea.</article-title>
            <source>Am J Med</source>
            <year>2004</year>
            <month>Mar</month>
            <day>15</day>
            <volume>116</volume>
            <issue>6</issue>
            <fpage>363</fpage>
            <page-range>363-8</page-range>
            <pub-id pub-id-type="pmid">15006584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oliveros-Ruiz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vallejo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Diez Canseco</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>C&#x000e1;rdenas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hermosillo</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Determinants of thyrotoxic cardiomyopathy recovery.</article-title>
            <source>Biomed Res Int</source>
            <year>2013</year>
            <volume>2013</volume>
            <fpage>452709</fpage>
            <pub-id pub-id-type="pmid">24106705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McMurray</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cohen-Solal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dietz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eichhorn</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Erhardt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hobbs</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Krum</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Maggioni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McKelvie</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Pi&#x000f1;a</surname>
                <given-names>IL</given-names>
              </name>
              <name>
                <surname>Soler-Soler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Swedberg</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.</article-title>
            <source>Eur J Heart Fail</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>710</fpage>
            <page-range>710-21</page-range>
            <pub-id pub-id-type="pmid">16087129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Philipson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ekman</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Forslund</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Swedberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schaufelberger</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Salt and fluid restriction is effective in patients with chronic heart failure.</article-title>
            <source>Eur J Heart Fail</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>15</volume>
            <issue>11</issue>
            <fpage>1304</fpage>
            <page-range>1304-10</page-range>
            <pub-id pub-id-type="pmid">23787719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>WRITING COMMITTEE MEMBERS</collab>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Jessup</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Filippatos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Givertz</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Hollenberg</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Lindenfeld</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Masoudi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>McBride</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Westlake</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.</article-title>
            <source>Circulation</source>
            <year>2016</year>
            <month>Sep</month>
            <day>27</day>
            <volume>134</volume>
            <issue>13</issue>
            <fpage>e282</fpage>
            <page-range>e282-93</page-range>
            <pub-id pub-id-type="pmid">27208050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huynh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bernardo</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>McMullen</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Ritchie</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways.</article-title>
            <source>Pharmacol Ther</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>142</volume>
            <issue>3</issue>
            <fpage>375</fpage>
            <page-range>375-415</page-range>
            <pub-id pub-id-type="pmid">24462787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calderon</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Merchan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Rozo</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Guerrero</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Treistman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sulak</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Cheong</surname>
                <given-names>BY</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mesa</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Intrapericardial primary thymic carcinoma in a 73-year-old man.</article-title>
            <source>Tex Heart Inst J</source>
            <year>2008</year>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>458</fpage>
            <page-range>458-61</page-range>
            <pub-id pub-id-type="pmid">19156242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ho</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Pinsky</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kannel</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The epidemiology of heart failure: the Framingham Study.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>1993</year>
            <month>Oct</month>
            <volume>22</volume>
            <issue>4 Suppl A</issue>
            <fpage>6A</fpage>
            <page-range>6A-13A</page-range>
            <pub-id pub-id-type="pmid">8376698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McKenna</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Behr</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death.</article-title>
            <source>Heart</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>87</volume>
            <issue>2</issue>
            <fpage>169</fpage>
            <page-range>169-76</page-range>
            <pub-id pub-id-type="pmid">11796562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mehra</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Canter</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Hannan</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Semigran</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Uber</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Baran</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Danziger-Isakov</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kirklin</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Kirk</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kushwaha</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Lund</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Potena</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Verschuuren</surname>
                <given-names>EAM</given-names>
              </name>
              <name>
                <surname>Zuckermann</surname>
                <given-names>A</given-names>
              </name>
              <collab>International Society for Heart Lung Transplantation (ISHLT) Infectious Diseases, Pediatric and Heart Failure and Transplantation Councils</collab>
            </person-group>
            <article-title>The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-23</page-range>
            <pub-id pub-id-type="pmid">26776864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18915.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feltner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Cen&#x000e9;</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Sueta</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Coker-Schwimmer</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Arvanitis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lohr</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Middleton</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Jonas</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis.</article-title>
            <source>Ann Intern Med</source>
            <year>2014</year>
            <month>Jun</month>
            <day>03</day>
            <volume>160</volume>
            <issue>11</issue>
            <fpage>774</fpage>
            <page-range>774-84</page-range>
            <pub-id pub-id-type="pmid">24862840</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
